Janux Therapeutics Inc. (JANX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation.
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last?
Janux Therapeutics (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
Janux Therapeutics' expanded pipeline, especially the ARM platform for autoimmune diseases, offers significant long-term upside given its large addressable market and strong preclinical data. The company boasts exceptional financial stability, with over $1 billion in cash and a 5-6 year runway, minimizing near-term dilution risk for investors. Despite promising science, all assets are in early development, making JANX a high-risk, long-term speculative Buy for investors with high-risk tolerance.
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates.
